MedPath

A randomised double blind controlled trial of oral ephedrine/etilefrine in the prevention of recurrent (stuttering) attacks of priapism in sickle cell disease: a multicentre international study in older children and adults

Completed
Conditions
Sickle cell disease
Haematological Disorders
Sickle-cell disorders
Registration Number
ISRCTN54312363
Lead Sponsor
Aintree University Hospitals NHS Foundation Trust (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
320
Inclusion Criteria

1. Male patients with a documented history of sickle cell disease (SCD) irrespective of genotype (alpha thalassemia status will not be determined)
2. Patients should be 12 years or over
3. Patients with a known history of stuttering priapism (a short self limiting episode lasting up to 4 hours which tends to be recurrent) attributable to SCD
4. Patients in active attendance at a designated care centre i.e. one visit in the last six months
5. Patients on a stable dose of hydroxyurea for over six months before trial entry, provided a baseline event rate (on treatment) is established before randomisation and no dose change occurs during trial period
6. Patients who received a one-off or isolated top up transfusion greater than three months before recruitment date can be entered into study

Exclusion Criteria

1. Patients with sickle cell trait (haemoglobin A greater than haemoglobin S on alkaline gel electrophoresis or high performance liquid chromatography (HPLC) will not be eligible for randomisation
2. Patients known to have elevated blood pressure or a history of cardiac disease
3. Patients with SCD and a documented history of stroke in the past
4. Patients with a history of acquired vessel aneurysm in the past
5. Patients known to be on MAOI (monoamine oxidase inhibitor) drugs or other drugs with significant interactions with study drugs
6. Patients known to be intolerant of adrenergic drugs
7. Patients with hyperthyroidism
8. Patients on a long-term blood transfusion programme to prevent or treat the complications of SCD

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. A change in the frequency of attacks of stuttering priapism from baseline data<br>2. A change in the incidence of an acute (major) attacks of priapism
Secondary Outcome Measures
NameTimeMethod
Tolerability of oral etilefrine (50 mg) or ephedrine at 15 mg or 30 mg with respect to side effect profile.
© Copyright 2025. All Rights Reserved by MedPath